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Multi-drug resistant (MDR) bacteria, especially MDR Gram-
negative bacteria, are a rising public health threat. Without
effective antibiotic therapy, many mainstays of modern medicine 
such as chemotherapy and major surgery would not be possible.1
This high unmet medical need has been noted by societies,2
governments,3 and even the United Nations.4 Due to this, the need 
to discover and develop novel treatments for resistant bacterial 
infections is higher than ever. To address this need, new ways of 
working are required.5 One example of this is the Innovative 
Medicines Initiative’s ENABLE project, whose aim is to optimize 
hits and leads which target Gram-negative bacteria in semi-open 
innovation, consortium format.6 As part of the ENABLE project, 
we recently reported a series of thiophene-based antibacterials
which target the bacterial topoisomerase DNA gyrase via binding 
to a previously unidentified allosteric site on the enzyme.7 The 
bacterial topoisomerases DNA gyrase and topoisomerase IV are 
essential enzymes which control DNA topology and are the targets 
of the clinically validated fluoroquinolone antibiotics, in addition 
to several other classes reported in the literature8 or in clinical 
development.9
The thiophene-based antibacterial 1 (Figure 1) is an inhibitor 
of bacterial DNA gyrase with modest antibacterial activity against
a range of Gram-negative bacterial pathogens.7 Unlike most other 
inhibitors of bacterial topoisomerases, the lead compound 1 only 
showed significant activity against DNA gyrase with essentially 
no activity against the related enzyme topoisomerase IV (IC50
>500 µM7 in a decatenation of kinetoplast DNA inhibition assay). 
As part of an overall medicinal chemistry program on this series,
we sought to modify the core of these inhibitors. Examination of 
the binding mode of 1 to Staphylococcus aureus (S. aureus) DNA 
gyrase7 (Figure 3A) suggested that two cyclization strategies to 
bicyclic templates could be tolerated (Figure 1). Ring closure 
route a retains the thiophene core and fuses a 6-ring heterocycle,
while ring closure route b changes the thiophene to a 6-membered
benzo- or heterocycle and fuses a 5- or 6-membered heterocycle. 
We hypothesized that appropriately constraining the core10 might 
improve biochemical activity at DNA gyrase; here we report our 
results on the synthesis and evaluation of exemplars of both
cyclization approaches (Figure 2). 
The gyrase inhibitors 2 through 12 (Figure 2) were synthesized 
as described in Schemes 1-7. The synthesis of thieno[3,2-
d]pyrimidin-4(3H)-one core inhibitor 2, derived from ring closure 
route a (Figure 1), started with commercially available thiophene 
13 (Scheme 1). Installation of the 2-chlorophenyl group via 
Suzuki coupling followed by saponification provided the 
corresponding carboxylic acid. PyBOP-mediated coupling with 
the protected (S)-phenylethylenediamine provided 14. Heating in 
the presence of trimethoxymethane and acetic anhydride provided 
the cyclized product which was deprotected with trifluoracetic 
acid to give compound 2.
AB ST R ACT
A series of DNA gyrase inhibitors were designed based on the X-ray structure of a parent thiophene scaffold with the objective to improve 
biochemical and whole-cell antibacterial activity, while reducing cardiac ion channel activity.  The binding mode and overall design hypothesis of 
one series was confirmed with a co-crystal structure with DNA gyrase. Although some analogs retained both biochemical activity and whole-cell 
antibacterial activity, we were unable to significantly improve the activity of the series and analogs retained activity against the cardiac ion channels, 
therefore we stopped optimization efforts. 
Figure 1.  Gyrase inhibitor 1 and new bicyclic designs.
Figure 2.  DNA gyrase inhibitors disclosed in this paper.
Scheme 1. Reagents and conditions: (a) 2-chlorobenzeneboronic acid, 
K2CO3, Pd(PPh3)4, dioxane, H2O, 100 ºC, 98%; (b) LiOH, MeOH, H2O, 86%; 
(c) N-Boc-(S)-phenylethylenediamine, iPr2NEt, PyBOP, MeOH, 67%; (d) 
trimethoxymethane, Ac2O 100 ºC, 25%; (e) TFA, CH2Cl2, 61%.
The synthesis of 3 and derivatives 11 and 12 is described in 
Scheme 2.  Arylation of bromide 15 provided 16 followed by 
formation of the N-hydroxy amide under basic conditions followed 
by cyclization with carbonyldiimidazole provided the key 
benzisoxazolone intermediate 17.  Treatment with alcohol 18 
under Mitsunobu conditions afforded the desired O-alkylated
product 21. Formation of the HCl salt afforded target compound 3. 
Alternatively, reaction of 21 with 1H-pyrazole-1-
carboximidamide followed by HCl salt formation provided the 
guanidine analog 12. In an analogous manner, intermediate 17 was 
coupled with Boc-protected 2-amino-1-(pyridin-2-yl)ethanol (19),
followed by deprotection and salt formation to give target 11.  
Scheme 2. Reagents and conditions: (a) 2-chlorobenzeneboronic acid, CsF, 
Pd(PPh3)4, DMF, H2O, 100 ºC, 30%; (b) NH2OH, dioxane, aq. NaOH, 89%.; 
(c) CDI, Et3N, THF, 60 ºC, 79%; (d) alcohol, PPh3, DIAD, THF, rt; (e) TFA, 
CH2Cl2,; (f) 1H-pyrazole-1-carboximidamide, iPr2EtN, CH2Cl2, 49% over 2 
steps; (g) HCl, Et2O; (h) 1) MeNO2. Triton-B, MeOH, 0 ºC; 2) LiAlH4, THF, 
40 ºC, Boc2O, NaHCO3, THF/H2O (5% over 3 steps).
The synthesis of O-alkylated indazoles 4 and 5 proceeded with 
a similar route and is shown in Scheme 3, starting with Suzuki
coupling and methyl ester formation to give 24.  Displacement of 
the aryl fluoride with hydrazine at 100 ºC, followed by 
protection/activation with Boc-anhydride and treatment with a 
strong base gave the indazolanone core 25. Mitsunobu reaction 
with alcohol 18 followed by removal of the Boc group with 
trifluoracetic acid and swapping to the HCl salt gave target 
compound 4. Selective protection of the primary amine of 4 with 
Boc-anhydride followed by methylation of the indazole nitrogen
with iodomethane, deprotection, and salt switching gave 
compound 5. 
Scheme 3. Reagents and conditions: (a) 2-chlorobenzeneboronic acid, 
Cs2CO3, Pd(PPh3)4, dioxane, H2O, 100 ºC, 91%; (b) SOCl2, tol, MeOH, 92%; 
(c) hydrazine, MeOH, 100 ºC, 75%; (d) Boc2O, iPr2NEt, DMAP, CH2Cl2; (e) 
aq. NaOH, 71% over 2 steps; (f) 19, PPh3, DIAD, THF, rt; 73%; (g) TFA, 
CH2Cl2; (h) HCl, Et2O, 67% over 2 steps; (i) Boc2O, NaHCO3, THF, 0 ºC; (j) 
MeI, K2CO3, DMF; (k) TFA, CH2Cl2; (l) HCl, Et2O, 33% over 4 steps from 5.
The synthesis of the N-alkylated indazoles 6 and 7 started with 
arylation of 5-bromo-indazole (26) followed by iodination in the 
presence of a strong base to give compound 27 (Scheme 4). 
Blocking the N1-H upon reaction with either Boc-anhydride or 
iodomethane provided compounds 28 and 29, respectively, which 
were each aminated using palladium catalysis and benzophenone 
imine followed by treatment with hydroxylamine to give the 3-
amino analogs 30 and 31, respectively. Heating with nitrostyrene 
provided the 1,4-addition products which were reduced with nickel 
boride in cold THF/methanol. Trifluoracetic acid deprotection of 
the N-Boc group of 30 and formation of the HCl salt provided 
target compound 6.  Target 7 was made similarly from 31 by 
simple formation of the HCl salt following reduction of the 
nitrostyrene adduct. 
Scheme 4. Reagents and conditions: (a) 2-chlorobenzeneboronic acid, 
Cs2CO3, Pd(PPh3)4, dioxane, H2O, 160 ºC, 70%; (b) I2, KOH, DMF; (c) Boc2O,
Et3N, DMAP, CH3CN, 75% over 2 steps; (d) MeI, K2CO3, DMF, 90%; (e) 
benzophenone imine, Pd2(dba)3, xantphos, Cs2CO3, dioxane, 100 ºC, (f) 
NH2OH, MeOH, 45-47% over 2 steps; (g) nitrostyrene, 60 ºC, 46-53%; (h) 
NiCl2, NaBH4, MeOH, THF, -20 ºC; (i) TFA, CH2Cl2; (j) HCl, Et2O. 
The synthesis of isoquinoline 8 started with SNAr reaction of 
compound 32 with mono-protected diamine 33 (Scheme 5). 
Suzuki coupling with 2-chlorobenzeneboronic acid provided 
compound 34 followed by deprotection of the N-Boc group, and 
formation of the HCl salt gave target compound 8. 
Scheme 5. Reagents and conditions: (a) 34, Pyridine, 145 ºC microwave; 
(b) 2-chlorobenzeneboronic acid, Cs2CO3, Pd(PPh3)4, dioxane, H2O, 130 ºC
microwave; (c) TFA, CH2Cl2; (d) HCl, Et2O, 12% over 4 steps.
Synthesis of the pyridylisoxazole 9 is shown in Scheme 6.  
Treatment of 5-bromo-2-hydroxynicotinic acid (35) with thionyl 
chloride and methanol with a catalytic amount of DMF provided 
the corresponding methyl ester. Formation of the N-hydroxyamide 
followed by sodium hydroxide-promoted cyclization gave the 
fused isoxazolopyridinone 36. Successive Mitsunobu reaction
with alcohol 18, Suzuki coupling, deprotection and HCl salt 
formation gave the target 9.
Scheme 6. Reagents and conditions: (a) SOCl2, DMF, MeOH, 65 ºC, 98%; 
(b) NH2OH, dioxane, aq. NaOH, 94%; (c) NaOH, 70 ºC, 59%; (d) PPh3, DIAD, 
THF, rt, 68%; (e) 2-chlorobenzeneboronic acid, CsF, Pd(PPh3)4, DMF, H2O, 
100 ºC, (f) TFA, CH2Cl2; (g) HCl, Et2O, 18% over 3 steps.
Scheme 7 shows the synthesis of inhibitor 10. Conversion of 
38 to the corresponding methyl ester followed by bromination 
gave compound 39. Suzuki coupling followed by treatment with 
hydroxylamine under basic conditions gave compound 40.
Cyclization with carbonyldi-imidazole gave intermediate 41
which was treated with alcohol 18 under Mitsunobu conditions, 
followed by deprotection and formation of the HCl salt to give 10.
Scheme 7. Reagents and conditions: (a) TMSCHN2, CH2Cl2, MeOH; (b) 
Br2, H2O, 42 % over 2 steps; (c) 2-chlorobenzeneboronic acid, CsF, Pd(PPh3)4, 
DMF, 100 ºC, 16%; (d) NH2OH, dioxane, aq. NaOH.; (e) CDI, Et3N, CH2Cl2, 
23% over 2 steps; (f) 19, PPh3, DIAD, THF, rt; (g) TFA, CH2Cl2 (h) HCl, Et2O, 
29% over 3 steps.
The cyclized analogs of compound 1 were initially tested in a 
DNA gyrase biochemical assay11 and profiled against a panel of 
Gram-negative organisms,12 in addition to a mammalian 
cytotoxicity assay in mouse LY5178Y TK +/- cells13 (Table 1). 
Inhibitor 2, representing ring closure strategy a (Figure 1), 
retained modest inhibition of DNA gyrase and demonstrated an 
improvement in cytotoxicity over the parent thiophene analog.  
Unfortunately, no whole cell antibacterial activity was observed 
across the range of wild-type (WT) Gram-negative pathogens 
tested (MICs >128 µg/mL). Activity could be detected when efflux 
was impaired by deletion of tolC in Escherichia coli (E. coli ΔtolC
MIC = 2-4 µg/mL) suggesting that efflux was a contributor to the 
lack of WT antibacterial activity.14 On-target activity at DNA 
gyrase was confirmed by an 8-fold shift in MIC against an E. coli
ΔtolC GyrB E793K7 target mutant (a mode-of-action tool strain) 
relative to the isogenic parental strain. Due to the lack of activity
against WT strains, additional analogs in this series were not 
pursued.
Initial investigation of the scope of ring closure strategy b
(Figure 1) resulted in compounds 3-8, representing 3-O-alkyated 
benzoisoxazoles, 3-O- and 3-N-alkyated indazoles, and 1-N-
alkylated isoquinolines. The benzoisoxazole 3 demonstrated 
promising DNA gyrase biochemical activity and modest (8-16 
µg/mL) activity against WT E. coli and Acinetobacter baumannii
(A. baumannii), with activity against Klebsiella pneumoniae (K. 
pneumoniae) and Pseudomonas aeruginosa (P. aeruginosa) being 
considerably weaker (MICs ≥128 µg/mL, not shown). Very potent 
activity was observed in the efflux knock-out stains and the ≥16-
fold shift in MIC in the GyrB E793K mutant demonstrated on-
target activty (Table 1).  
To confirm that the binding mode of compound 3, we initially 
solved a 2.7Å co-crystal structure with S. aureus DNA gyrase and
20-12p-8 double nicked DNA.15 This showed that compound 3
indeed bound as expected (Figure 3B) to the same allosteric site 
as compound 1.7 The DNA used for this structure contained 
artificial nicks at each binding site, and the central four base-pairs 
of the DNA were not well defined in electron density maps. To try 
to obtain a clear view of a DNA-cleavage complex with compound 
3 (see next paragraph), we repeated the structural studies using a 
purified DNA-cleavage complex with 20-447T DNA.15 We 
obtained a 3.4Å crystal structure of compound 3 co-crystallized 
with a purified DNA-cleavage complex of S. aureus gyrase. This 
3.4Å structure showed compound 3 bound as seen in the 2.7Å 
structure, as expected (data not shown).
We have previously reported that compound 1 gave both single-
and double-stranded DNA cleavage with E. coli DNA gyrase.7
Using a fusion truncate of DNA gyrase from K. pneumoniae, we 
showed that compound 3 also enhanced single-stranded and 
double-stranded DNA cleavage products (data not shown) 
indicating the mechanism of action of compound 3 is via 
stabilization of ternary cleaved complexes. In addition to 
inhibition of DNA gyrase (IC50 = 0.16 µM, Table 1), compound 3
weakly inhibited E. coli TopoIV activity (IC50 was ~ 90 µM in a 
decatenation of kinetoplast DNA inhibition assay16) and induced 
TopoIV-mediated DNA cleavage breaks (data not shown), and
was also weakly active against the human enzyme (IC50 was ~210 
µM against human topoisomerase II in a decatanation of kDNA 
inhibition assay16).
Encouraged by the initial data of compound 3 and validation of 
the ring closure b hypothesis, several related 5,5 and 5,6 fused 
heterocycles were prepared (4-8). Relative to compound 3, these 
analogs had reduced DNA gyrase activity and weaker 
antimicrobial activity in WT and efflux knock-out strains of E. coli
and WT A. baumannii (Table 1). Interestingly, slight 
improvements in activity against K. pneumoniae relative to 
compound 3 were observed for some analogs. Like compound 3, 
none of the newer analogs possessed activity against WT P. 
aeruginosa (MIC >128 µg/mL). Unfortunately, whole cell on-
target activity was not demonstrated for these analogs as no MIC 
shift was observed in the E. coli GyrB E793K mutant, perhaps 
suggesting that some of the activity observed is not solely due to 
inhibition of DNA gyrase.
Figure 3. A) 2.22 Å crystal structure (pdb code: 5NPP) of 1 (yellow carbons) 
in complex with S. aureus DNA gyrase (GyrA blue carbons, GyrB magenta 
carbons) and DNA (green atom, lower left)7. Nitrogens blue, oxygens red, 
phosphorous orange chlorine green. Semi-transparent surface is shown on 
GyrA but not GyrB. Semi-transparent surface is shown on GyrA but not GyrB. 
Hydrogen bonds (dotted yellow lines) from E634 (=E793 in E.coli) go to 1 and 
R630. R630 also forms H-bonds to 1. B) 2.7 Å crystal structure of 3 (white 
carbons) in complex with S. aureus DNA gyrase and DNA (pdb code: 6QX1).
Hydrogen bond is shown as black dotted line. Note, the hydrogen bonds from  
R630 to 3 is similar to that in panel A from R630 to 1; but no H-bonds are 
observed to E634 with 3 (maybe because of a small movement of the end of 
the side-chain of R630). C) Superposition of crystal structures in A and B. 
Figure drawn with pymol (The PyMOL Molecular Graphics System,
Schrödinger, LLC). 
As analogs 4-98 displayed disappointing antibacterial 
activities, we returned to the benzisoxazole scaffold of compound 
3 and synthesized the three aza-analogs 9-11 and the guanidine 12. 
Although all analogs retained modest to good levels of activity 
against DNA gyrase, none showed an improvement in antibacterial 
activity in either WT or efflux strains of E. coli (12 gave a 2-fold
improvement against A. baumannii, Table 2). No activity (MIC 
>128 µg/mL) was observed against K. pneumoniae and P. 
aeruginosa, except for compound 12 which gave an MIC of 16
µg/mL against both K. pneumoniae and P. aeruginosa (data not 
shown). On-target activity was maintained for some (e.g. 9 and 11) 
but was less clear for analogs 10 and 12.  Indeed, the broader
spectrum activity of compound 12 could be due to an additional
non-specific mechanism of action, potentially related to the 
guanidine substituent which is installed in an effort to alter the 
polarity of the series.
Despite the disappointing antibacterial activity, we tested 
several analogs against cardiac ion channels to determine if 
rigidifying the core would impact these activities (Table 2). 
Although 3 did have attenuated inhibition of both the hERG17 and 
NaV1.518 channels compared to compound 1 (Table 2), the effect 
was not dramatic. Compounds 9, 10, and 12 also retained relatively 
potent inhibition against one or both of the cardiac ion channels
tested, highlighting the difficulty in optimizing safety parameters 
in addition to activity in antibacterial research and development.  
In summary, we have synthesized and tested several 5,6 and 6,6 
fused core analogs of thiophene antibacterial 1 . Although both 
initial design hypotheses were successful in delivering analogs 
with in vitro activity against DNA gyrase, none of the analogs had 
improved whole cell antibacterial activity relative to the parent 
compound 1. Moreover, several liabilities of the series, 
specifically cytotoxicity and cardiac ion channel activity, were not 
mitigated with this ring-fusion strategy. As such, we stopped work 
on the present ring-fusion approach. A complete account of our
efforts on monocyclic series, including liabilities and reasons for 
termination,7 will be reported separately.























1 0.04 ≤0.125 4 8 ≤0.125 32 4 5
2 2.0 2 16 >128 2-4 >128 >128 16
3 0.16 ≤0.125 2 8-16 ≤0.125 ≥128 8 10
4 1.6 2 2 32 2 32 32 3
5 5.0 2 2 >128 2 >128 64 nd
6 3.2 4 4 128 4 64 64 5
7 7.9 4 4 >128 4 >128 128 5
8 10 2 2 64 2 32 32 3




























1 0.04 ≤0.125 4 8 ≤0.125 4 5 6.7 13
3 0.16 ≤0.125 2 8-16 ≤0.125 8 10 23 22
9 0.5 1 16 64 1 64 20 nd 24
10 1.6 8 16 >128 4 >128 5 3.6 16
11 0.5 0.25 8 64 0.25 32 3 nd nd
12 0.16 0.25 0.5 8 0.25 4 11 9.5 nd
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the gyrase/DNA complex (with no drug) were pooled and 
concentrated to approximately 15 mg/ml. Crystallization: The 
DNA/protein complex was diluted 2:1 with 20 mM HEPES pH 7.0 
to reduce the Na2SO4 concentration and compound 3 was added to 
an end concentration of approximately 600 µM compound and 5% 
DMSO. Crystallization under paraffin oil was set up in Terazaki 
plates with 0.7 µl protein and 2.8 µl well buffer (7.5-10% PEG  
5000 MME, 130-190 mM BisTris pH 6.2). The crystallizations
were set up in the presence and absence of 25mM MgCl2. Before 
adding the oil, the drops were streak-seeded. The crystals were 
cryo-protected in 15% Glycerol, 20% PEG 5000 MME, 150 mM 
BisTris pH6.2, 2 mM EDTA, 2 mM compound before flash freezing 
in liquid nitrogen for data collection at the synchrotron. This 
complex of compound 3 with cleaved DNA gave a 3.4Å structure 
with six complexes in the asymmetric unit deposited with PDB 
code: 6qx2.
16. E.coli topoisomerase IV assays were performed as follows: 1 U of 
topo IV (final assay concentration 15 nM) was incubated with 200 
ng kDNA DNA in a 30 μl reaction at 37ºC for 30 minutes under the 
following conditions: 50 mM HEPES-KOH (pH 7.6), 100 mM 
potassium glutamate, 10 mM magnesium acetate, 10 mM 
dithiothreitol, 1 mM ATP and 50 µg/ml BSA. 
Human topoisomerase II alpha assays were performed as follows: 
1 U of human topo IIα (final assay concentration 1.9 nM) was 
incubated with 200 ng kDNA in a 30 μl reaction at 37°C for 30 
minutes under the following conditions: 50 mM Tris HCl (pH 7.5), 
125 mM NaCl, 10 mM MgCl2,  5 mM DTT,  0.5 mM EDTA,  0.1 
mg/ml bovine serum albumin (BSA) and 1 mM ATP.
All reactions were stopped by the addition of 30 μl chloroform/iso-
amyl alcohol (24:1) and 20 μl Stop Dye (40% sucrose, 100 mM 
Tris.HCl ( pH 7.5), 10 mM EDTA, 0.5 μg/ml bromophenol blue), 
before being loaded on a 1.0% TAE (Tris.acetate 0.04 mM, EDTA 
0.002 mM) agarose gel. Gels were run at 90V for 2 hours. Bands 
were visualised by ethidium bromide staining for 20 minutes. Gels 
were scanned using gel documentation equipment (GeneGenius, 
Syngene, Cambridge, UK) and IC50s were obtained with gel 
scanning software. (GeneTools, Syngene, Cambridge,UK) Raw gel
data (fluorescent band volumes) collected from Syngene, 
GeneTools gel analysis software were converted to a % of the 100% 
control (the fully decatenated substrate) These were analysed using 
SigmaPlot Version 13.0 (2015). (Enzymes and substrates provided 
by Inspiralis Ltd)
17. hERG Qpatch assay as previously described in: Haile. P.A.; 
Casillas, L.N.;  Bury, M. J.; Mehlmann, J.F.; Singhaus, Jr., R.;  
Charnley, A.K.; Hughes, T.V.; DeMartino, M.P.; Wang, G.Z.; 
Romano, J.J.; Dong, X.; Plotnikov, N.V.; Lakdawala, A.S.; 
Convery, M.A.; Votta, B.J.; Lipshutz, D.B.; Desai, B.M.; Swift, B.; 
Capriotti, C.A.; Berger, S.B.; Mahajan, M.K.; Reilly, M.A.; Rivera, 
E.J.; Sun, H.H.; Nagilla, R.; LePage, C.; Ouellette, M.T.; Totoritis, 
R.D.; Donovan, B.T.; Brown, B.S.; Chaudhary, K.W.; Gough, P.J.; 
Bertin, J.; Marquis, R.W. Identification of Quinoline-Based RIP2 
Kinase Inhibitors with an Improved Therapeutic Index to the hERG 
Ion Channel. ACS Med. Chem. Lett. 2018, 26, 1039-1044..
18. NaV1.5 Qpatch assay: Cell culture, assay solutions and growth 
medium are identical to that described in Donovan, B.T.;  Bakshi, 
T.; Galbraith, S.; Nixon, C.J.; Payne, L.A.; Martens, S.F.  Utility of 
frozen cell lines in medium throughput electrophysiology screening 
of hERG and NaV1.5 blockade.  J. Pharmacol. Toxicol. Methods, 
2011, 64, 269–276, with the following exceptions: Cell line: The 
HEK293-based NaV1.5 expressing cell line was derived in-house 
by GSK Biological Reagents and Assay Design group.  The parental 
cell line, the ATCC line HEK293 cell line CRL-1573 was 
transfected with the Homo sapiens cardiac sodium voltage-gated 
channel, hNaV1.5 (type V, α subunit, SCN5A, Entrez gene id: 
6331).  For NaV1.5 experiments, all protocols were sampled at 20 
kHz and filtered with a 4th order Bessel filter with a 200 Hz cutoff.  
Series resistance was compensated at 50%.  The holding potential 
was -120 mV.  The stimulus protocol consisted of holding each cell 
at −120 mV for 20 ms, stepping to −30 mV for 50 ms and returning 
to the −120 mV holding potential. The command protocol was
delivered every 2 s (0.5 Hz). A separate assay was run with the 
command protocol delivered every 500 ms (2 Hz) to check for signs 
of frequency dependent effects on potency. Data reported in Table 
2 correspond to the 0.5 Hz assay. Signal was measured at each 
sweep was the difference between the maximum inward current 
seen in the first 10ms of the −30 mV depolarizing step minus the 
mean current seen in the last 5 ms of the same step.  Currents were 
recorded at room temperature on the Sophion Qpatch 48 HTX 
(Sophion Biosciences).  Cells which had NaV1.5 currents greater 
than 0.25 nA were used for experiments, although the amplitude 
was usually much higher (~2.5 nA).  For all concentration response 
curve experiments, a negative control consisting of external 
solution with 0.3% DMSO bracketed the concentration–response 
dilution series. After the second negative control was added, a 
positive control of 1000 μM quinidine was added to fully block all 
current.  Inhibition data were normalized between the negative and 
positive controls.  All solutions on each plate were matched for 
vehicle concentration, 0.3% DMSO.  Above that concentration 
peak current amplitude dropped significantly.  In all experiments, 
each test solution concentration was added three times (10 μl each 
addition for 30 μl total, 3 s apart) and given 5 min to reach steady-
state.  Rundown compensation, where necessary, was done with a 
linear fit anchored to the end of the control state. Curve fitting: all 
signals were analyzed using Sophion Qpatch software version 5.0.  
Data was collated using Microsoft Excel and all subsequent 
analyses were done using GraphPad Prism version 6.05 for 
Windows (GraphPad Software, La Jolla, California USA, 
www.graphpad.com).  Measurements were fit to a four-parameter 
logistic fit for dose-response curves: y = bottom + (top-bottom) / 
(1+10^((logEC50-x) * Hill slope)).
